In 1971, Folkman[1] hypothesized that inhibition of tumor angiogenesis is a potentially powerful tool for cancer therapy.[2–6] With the identification of more and more new molecules modulating angiogenesis,[6–8] targeting tumor angiogenesis has become increasingly likely, and the concept of inhibiting tumor vessel growth has led to the discovery of vascular endothelial growth factor (VEGF) and the anti-VEGF antibody, Bevacizumab (Avastin). Here, VEGFA is linked to cancer.